Genetics-based matching to prevent or slow type 1 diabetes
Using genetics in the selection of candidates for therapies to prevent type 1 diabetes and its progression.
This project uses genetic information to find adults with or at risk for type 1 diabetes who are most likely to benefit from treatments that prevent or slow the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11479587 on NIH RePORTER |
What this research studies
If you join, researchers will use your genetic information along with clinical data to calculate a type 1 diabetes genetic risk score and look for specific genetic markers linked to disease progression or treatment response. They will compare genetic profiles from people in TrialNet prevention and treatment groups to see which markers predict progression before diagnosis and preservation of beta-cell function after diagnosis. The team will refine genetic risk models and test whether genetics can help match individuals to disease-modifying therapies. The data and tools developed will be shared with other researchers to help make genetic matching practical in clinical care.
Who could benefit from this research
Good fit: Ideal candidates are adults with signs of early or recent-onset type 1 diabetes (for example positive autoantibodies or recent diagnosis) or people enrolled in TrialNet prevention or recent-diagnosis studies.
Not a fit: People without T1D-related genetic markers or those with long-standing type 1 diabetes who have already lost significant beta-cell function may be less likely to benefit.
Why it matters
Potential benefit: If successful, this work could help identify people most likely to benefit from therapies that prevent type 1 diabetes or preserve remaining insulin-producing beta cells, reducing unnecessary treatments.
How similar studies have performed: Previous TrialNet work has successfully used a type 1 diabetes genetic risk score to improve prediction and to explore links with treatment response, but using genetics to guide therapy selection is still being refined.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Redondo, Maria Jose — Baylor College of Medicine
- Study coordinator: Redondo, Maria Jose
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.